September 23, 2016 09:18 AM EDT
R&D

As politi­cians de­bate the pri­or­i­ty re­view vouch­er pro­gram, the FDA is root­ing for its demise

John Carroll

Editor & Founder

Sarep­ta’s reg­u­la­to­ry win on eteplirsen this week came with a big bonus. The ap­proval de­liv­ered a rare pe­di­atric pri­or­i­ty re­view vouch­er that the com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

Ex­clu­sive: Joe Jimenez's Adi­tum Bio rings in new year with $428M third fund

FDA of­fers suite of new guid­ance on AI, ac­cel­er­at­ed ap­provals, clin­i­cal tri­als and more

WuXi Bi­o­log­ics to sell Irish vac­cine site to Mer­ck for $500M

I-Mab stops work on CD73; Citius to pur­sue ‘strate­gic’ op­tions

Ex­clu­sive: AI biotech Iambic snags CFO who helped steer Re­cur­sion-Ex­sci­en­tia deal

A service from the Financial Times